Gracell Biotechnologies Inc. (NASDAQ:GRCL) saw an upside of 14.41% to $3.91 after adding $0.49 on Monday. The 5-day average trading volume is 175,768 shares of the company’s common stock. It has gained $4.00 in the past week and touched a new high 2 times within the past 5 days. An average of 190,852 shares of the company has been traded in the last 20 days, and the 50-day average volume stands at 383,615.
GRCL’s 1-month performance is -14.19% or -$1.01 on its low of $3.17 reached on 07/27/23. The company’s shares have touched a 52-week low of $1.40 and high of $6.99, with the stock’s rally to the 52-week high happening on 06/14/23. YTD, GRCL has achieved 70.13% or $1.25 and has reached a new high 21 times. However, the current price is down -44.02% from the 52-week high price.
Top 5 AI Stocks to Buy for 2023
The artificial intelligence (AI) revolution is already here. And it's about to change everything we know about everything.
According to Grand View Research, the global AI boom could grow from about $137 billion in 2022 to more than $1.81 trillion by 2030. And investors like you always want to get in on the hottest stocks of tomorrow. Here are five of the best ways to profit from the AI boom.
Click Here to Download the FREE Report.
Sponsored
Valuation Metrics
GRCL stock has a beta of -1.39. Moving on to other valuation ratios, the price-to-book (PB) in the most recent quarter is 1.38.
Gracell Biotechnologies Inc.’s quick ratio for the period ended March 30 was 6.80, with the current ratio over the same period at 6.80. As well, the company’s long term debt to equity for the quarter ending March 30 was 0.03, while the total debt to equity was 0.12.
Earnings Surprise
For the quarterly period ending March 30 this year, Gracell Biotechnologies Inc.’s cash and short-term investments amounted to $0.52 million against total debt of $182.62 million. Net income and sales went up compared to those figures reported in the previous quarter. Net income grew 19.16% to -$88.08 million, while revenue of $0.0 was 100.0% off the previous quarter. Analysts expected GRCL to announce -$0.39 per share in earnings in its latest quarter, but it posted -$0.35, representing a 10.30% surprise. EBITDA for the quarter stood at more than -$24.26 million. GRCL stock balance sheet for the quarter ending March 30 shows that total liabilities totaled 38.31 million, with total debt at $182.62 million.
Let’s look briefly at Gracell Biotechnologies Inc. (GRCL) price momentum from a technical analysis perspective. The 9-day relative strength index as at close on 04 August was 41.33% to suggest the stock is trending Neutral, with historical volatility in this time period at 156.42%.
The stock’s 5-day moving average is $3.53, reflecting a -5.84% or -$0.22 change from its current price. GRCL is currently trading -23.66% above its 20-day SMA, +95.05% above its 100-day SMA. However, the stock’s current price level is away from the SMA50 by +30.04% and SMA200 by+7.90%.
Stochastic %K and %D was 17.70% and 17.82% and the average true range (ATR) pointed at 0.46. The RSI (14) points at 43.60%, while the 14-day stochastic is at 20.77% with the period’s ATR at 0.48. The stock’s 9-day MACD Oscillator is pointing at -0.10 and -0.32 on the 14-day charts.
Analyst Ratings
Analysts offering their rating for GRCL stock have a consensus rating for the stock as Buy. Currently, 0 brokerage advisors rate GRCL as a “sell,”, while 0 advise that investors “Hold.” 0 analysts have rated the stock as underweight. 0 rates the stock as overweight while 7 have offered a “buy” rating.
What is GRCL’s price target for the next 12 months?
Analysts have a consensus price target ranging from a low of $7.00 and a high of $20.00, with their median price target at $12.00. Looking at these predictions, the average price target given by analysts is for Gracell Biotechnologies Inc. (GRCL) stock is $12.86.
